Moderna (NSDQ:MRNA) and Catalent (NYSE:CTLT) today announced a collaboration for large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine candidate (mRNA-1273) at Catalent’s biologics facility in Bloomington, Ind. Catalent will provide vial filling and packaging capacity, as well as additional staffing required for 24×7 manufacturing operations at the site to support production of an initial 100 million…
Legacy Pharmaceutical Packaging buys facility to expand third-party logistics
Legacy Pharmaceutical Packaging recently announced that it has bought a 215,000-square-foot open-space facility near its St. Louis area headquarters to support widescale third-party logistics and distribution services. The new facility, announced last week, nearly doubles Legacy’s total footprint to more than 500,000 square feet. The new space allows Legacy Pharmaceutical Packaging to significantly grow its…
Real estate firms tout former Bristol-Myers Squibb facility as an ‘innovation campus’
Lincoln Equities Group and H.I.G. Realty Partners announced today that they’ve acquired the 1.2 million-square-foot life sciences campus that Bristol-Myers Squibb owned outside Princeton, N.J. Brokerage firm JLL is helping the real estate outfits market the 433-acre “Princeton West Innovation Campus” in Hopewell, N.J., to life sciences companies as a secure, multipurpose research and development…
The Rapid Rise of Modular Construction—Are Standardized Facilities Next?
In recent years, the discussion for flexible facility needs became widespread. The motivations for such flexible facility needs are manifold, for example, the requirement to rapidly deploy additional manufacturing capacities or scalability without interrupting existing processes. In addition, the transformation of the treatment or patient base to more personalized medicines necessitates the need to rethink…
A Focus on West’s State-of-the-Art Waterford, Ireland Facility
West Pharmaceutical Services Inc.’s Waterford, Ireland facility is a global center of excellence for the company’s advanced manufacturing network. The facility, situated on a 44-acre campus, will produce West’s elastomeric laminate sheeting, which is used to package insulin for use in pen injectors. Additionally, it will offer high-value finishing for components, including stoppers and plungers,…
Swiss-Based Pharma Packager to Open First U.S. Manufacturing Plant in Spring
Switzerland-based Hoffmann Neopac, a global provider of packaging for a broad array of industries and applications, has earmarked two of its small-diameter Polyfoil tubes for production at its first U.S. manufacturing facility, which is scheduled to open in spring 2019. The 37,000-square-foot Wilson, NC plant will feature a high-speed tube line as part of an operation…
Two-Way Cloud Connectivity Can Trigger Ultimate Optimization Savings
Connecting to a cloud-based data center is now a crucial part of updating an HVAC system—especially for pharmaceutical companies. Pharmaceutical companies significantly can reduce energy consumption—and operational costs—by making their HVAC systems more efficient. Expansive facilities with precise manufacturing requirements tend to have large cooling, boiler, and air handling systems, which often run wastefully. Optimizing…
Catalent Invests $14 Million to Expand Biologics Packaging Capabilities
Catalent Pharma Solutions, a global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, has announced that following the site’s twentieth commercial product approval, it is investing nearly $14 million to expand biologics packaging capabilities and capacity at its Bloomington, Indiana, biologics manufacturing facility. Construction of the 15,000-square-foot facility…
Bayer Shedding 12,000 Jobs, Exiting Animal Care Business
In a strategic move, Bayer plans to cut as many as 12,000 jobs over the next few years, shed its animal care business, and exit from the Coppertone and Dr. Scholl’s consumer product lines. Most of the job cuts will come from operations in Germany, according to the company, which employs some 118,000 workers globally. Bayer…
Sandoz Abandoning U.S. Development of Rixathon
Novartis’ Sandoz division recently announced that it was no longer pursuing US approval for Rixathon, its biosimilar version of Roche’s Rituxan/MabThera (rituximab). Despite the fact that not seeking approval in the US is a lost opportunity in the short term, Sandoz’s strategy to prioritize other more profitable markets for Rixathon will benefit the company in…